Merck makes Indian bioscience acquisition
pharmafile | October 14, 2009 | News story | Research and Development |Â Â Asia, India, MerckÂ
Merck KGaA has bought an Indian company specialising in research products in a deal it says will make it one of the leading bioscience companies in the country.
Bangalore Genei (India) Private (BGIP) focuses on the development, production, marketing and sales of products for proteomic and genomic research.
Global head of Merck’s bioscience business Christina Shasserre said: “BGIP`s leadership in the Indian academic market, a segment with high growth potential, will ideally complement our existing customer base.
“BGIP`s product portfolio comprises a wide range of bioscience products, which are tailored to the needs of the domestic market in India.”
Located in Bangalore, BGIP has more than 100 employees and last year generated total revenues of 202 million rupees (3 million euros).
The company was acquired for an unspecified sum from the Sanmar Group and will be combined with Merck’s existing bioscience business.
Related Content

Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy
Merck have announced that they have entered into an agreement with private biotechnology company Curon …

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …

CHMP gives positive opinion for Merck’s KEYTRUDA for unresectable or metastatic urothelial carcinoma
Merck (known as MSD outside of the US and Canada) has announced that its anti-PD-1 …






